BCD-256 vs Litifilimab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Systemic Lupus Erythematosus
Shared mechanism: BDCA2 (CLEC4C) · full Systemic Lupus Erythematosus pipeline
BCD-256
Developed by Biocad
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Litifilimab
Developed by Biogen
NCT02847598 · Phase 2 · completed
This was a randomized, double-blind (participant and investigator), placebo-controlled trial with 264 enrolled participants and hard clinical primary endpoints (28-joint active joint count and CLASI-A skin activity score). The primary comparisons reached statistical significance in the favorable direction: Part A 450 mg vs placebo active-joint LS mean difference -3.4 (95% CI -6.7 to -0.2, p=0.037), and Part B CLASI-A LS mean differences -24.29 to -33.42 (p=0.015 to <0.001 across doses).
Next expected readout: May 2032 · NCT05352919 (registry estimate)
Reported efficacy
Part A: Change From Baseline in Active Joint Count (28-joint Assessment) to Week 24 (Baseline to Week 24); Part B: Percent Change From Baseline in Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) Score to Week 16 (Baseline to Week 16): Part A: Change From Baseline in Active Joint Count (28-joint Assessment) to Week 24 (Baseline to Week 24): Part A: BIIB059 50 mg -9 joints (Standard Deviation 5.7) | Part A: BIIB059 150 mg -13 joints | Part A: BIIB059 450 mg -14.5 joints (Standard Deviation 8.7) vs Part A: Placebo -12.7 joints (Standard Deviation 10.3) (met)
Result source: NCT02847598
Results for Systemic Lupus Erythematosus
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | BCD-256 | Litifilimab |
|---|---|---|
| SRI-4 | —Not reported | 56.3% vs 28.6%+27.7 vs placeboNCT028475982 other results
|
| BICLA | —Not reported | —Trial running · NCT04961567 |
| CLASI-50 | —Not reported | 64.1% vs 42.1%+22 vs placeboNCT028475988 other results
|
| Steroid sparing | —Not reported | —Trial running · NCT04961567 |
SRI-4
- BCD-256
- —Not reported
- Litifilimab
- 56.3% vs 28.6%+27.7 vs placeboNCT02847598
2 other results
- 16.7% vs 28.6% NCT02847598
- 33.3% vs 28.6% NCT02847598
BICLA
- BCD-256
- —Not reported
- Litifilimab
- —Trial running · NCT04961567
CLASI-50
- BCD-256
- —Not reported
- Litifilimab
- 64.1% vs 42.1%+22 vs placeboNCT02847598
8 other results
- 46.5% vs 21.9% NCT02847598
- 37.5% vs 12.1% NCT02847598
- 44% vs 21.9% NCT02847598
- 48% vs 12.1% NCT02847598
- 38.5% vs 21.9% NCT02847598
- 38.5% vs 12.1% NCT02847598
- 16.7% vs 42.1% NCT02847598
- 50% vs 42.1% NCT02847598
Steroid sparing
- BCD-256
- —Not reported
- Litifilimab
- —Trial running · NCT04961567
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
BCD-256: no structured comparison results are available for Systemic Lupus Erythematosus.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. BCD-256: 0 of 4 rows · Litifilimab: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Litifilimab |
|---|---|
| Dropout rate | 6.3%450 mg NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2 show 5 more results8.3%450 mg NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2 0%150 mg NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2 8%150 mg NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2 0%50 mg NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2 11.5%50 mg NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2 |
| Discontinued due to AEs | 0%450 mg NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2 show 5 more results2.1%450 mg NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2 0%150 mg NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2 0%150 mg NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2 0%50 mg NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2 0%50 mg NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2 |
| Serious AEs | 4.7%450 mg NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2 show 5 more results6.3%450 mg NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2 16.7%150 mg NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2 12%150 mg NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2 0%50 mg NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2 3.8%50 mg NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2 |
| Most frequent reported AEs | 450 mg fall 6.3% (placebo 1.8%) urinary tract infection 6.3% (placebo 7.1%) diarrhoea 4.7% (placebo 5.4%) NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2 show 5 more results450 mg injection site erythema 8.3% (placebo 0%) arthralgia 6.3% (placebo 3.6%) hypertension 6.3% (placebo 0%) NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2 150 mg influenza 33.3% (placebo 3.6%) anaemia 16.7% (placebo 0%) arthralgia 16.7% (placebo 3.6%) NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2 150 mg nasopharyngitis 20% (placebo 3.6%) pruritus 12% (placebo 3.6%) arthralgia 8% (placebo 3.6%) NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2 50 mg cystitis 16.7% (placebo 3.6%) diarrhoea 16.7% (placebo 5.4%) headache 16.7% (placebo 14.3%) NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2 50 mg headache 23.1% (placebo 14.3%) back pain 11.5% (placebo 0%) injection site erythema 11.5% (placebo 0%) NCT02847598 · Phase 2 · Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus · phase 2 |
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Litifilimab
show 2 more results
show 14 more results
show 8 more results
show 8 more results
show 8 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BCD-256's landscape · Litifilimab's landscape